Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 4Breast Neoplasms 3Multiple Myeloma 2Fallopian Tube Neoplasms 2Stomach Neoplasms 1Sarcoma 1Platinum-resistant Recurrent Ovarian Cancer 1Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation 1Ovarian Cancer Recurrent 1Lymphoma, Follicular 1Lymphoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Advanced Ovarian Cancer 1

Interventions

Paclitaxel 56Carboplatin 56Bevacizumab 43Gemcitabine 20Taxes 19pembrolizumab 15Immunoglobulin G 13Disulfides 13Topotecan 12olaparib 11Cisplatin 11niraparib 9Cyclophosphamide 9liposomal doxorubicin 8Specimen Handling 7Docetaxel 6Biopsy 6mirvetuximab soravtansine 5Nivolumab 5Magnetic Resonance Spectroscopy 5Letrozole 5Hyperthermic Intraperitoneal Chemotherapy 5Drug Therapy 5Cytoreduction Surgical Procedures 5Albumin-Bound Paclitaxel 5rucaparib 4pazopanib 4oregovomab 4Surgical Procedures, Operative 4Neoadjuvant Therapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Fallopian Tube Neoplasms × 1-dodecylpyridoxal × Clear all
NCT06787612 2026-05-20

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Regeneron Pharmaceuticals

Phase 2 Recruiting
220 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04983550 2021-07-30

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Unknown
126 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡